Acta Virologica Vol.61, No.1, p.3-12, 2017

Quarterly,
Founded: 1957
ISSN 0001-723X
E-ISSN 1336-2305

Published in English

Impact Factor = 1.82

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Acta Virologica Vol.61, No.1, p.3-12, 2017
Title: Antiviral therapy and prevention against hantavirus infections
Author: R. SZABÓ

Abstract: Hantaviruses are emerging zoonoses hosted by small mammals. In humans, they cause two diseases. Hemorrhagic fever with renal syndrome is mainly caused by Dobrava-Belgrade virus, Puumala virus, Seoul virus and Hantaan virus in Asia and Europe. On the other hand, the most important causes of hantavirus cardiopulmonary syndrome are Sin Nombre virus and Andes virus in Americas. Ribavirin yet remains the only licensed drug against the hantavirus infections, but its sufficient antiviral activity remains an issue under discussion. There are still no available vaccines against hantaviruses except of some inactivated virus vaccines licensed only in East-Asian countries. Some of the vaccines are under development in pre-clinical stages. The review discuses about specific compounds with approved antiviral activity against hantaviruses. Other approaches such as development of vaccines, are compiled as well.

Keywords: hantavirus; HFRS; HCPS; antiviral drugs; vaccines
	Published online: 28-Feb-2017
Year: 2017, Volume: 61, Issue: 1	Page From: 3, Page To: 12
doi:10.4149/av_2017_01_3
	download file

Aepress.sk